MOZIFER works by antagonising the CXCR4 receptor, promoting the release of stem cells into the bloodstream.
Recommended for:
Patients with multiple myeloma
Non-Hodgkin’s lymphoma
Prior to autologous hematopoietic stem cell transplant
When mobilisation with G-CSF alone is insufficient
Mobilisation of hematopoietic stem cells
Peripheral blood stem cell collection
Pre-transplant preparation in combination with G-CSF
MOZIFER is administered subcutaneously 6–11 hours before apheresis. It is used in combination with G-CSF, and dosage is based on patient weight.
Contraindications:
Hypersensitivity to plerixafor
Pregnancy and breastfeeding
History of severe allergic reactions
Side Effects:
Nausea, headache
Diarrhoea, dizziness
Injection site reactions
Elevated liver enzymes, leukocytosis